ArticleJournal of clinical virology : the official publication of the Pan American Society for Clinical Virology2013
Performance of the Alere Determine™ HIV-1/2 Ag/Ab Combo Rapid Test with specimens from HIV-1 seroconverters from the US and HIV-2 infected individuals from Ivory Coast.
Article in Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04793750 (Ending the HIV Epidemic Through Point-of-Care Technologies), which is not on this map. Cited by 46 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Ending the HIV Epidemic Through Point-of-Care Technologies (EHPOC): Performance Evaluation of Novel POC HIV Tests in Baltimore
Who cites it
46 citing papers in PubMed, 4 syntheses or guidelines pooled it, 76 citations in OpenAlex.
- 2025 US Public Health Service Guidelines for the Management of Occupational Exposures to Human Immunodeficiency Virus and Recommendations for Post-exposure Prophylaxis in Healthcare Settings.Infection control and hospital epidemiology · 2025Guideline
- Pooled it
- Field accuracy of fourth-generation rapid diagnostic tests for acute HIV-1: a systematic review.AIDS (London, England) · 2015Pooled it
- Incorporation of Social Determinants of Health in the Peer-Reviewed Literature: A Systematic Review of Articles Authored by the National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention.Public health reports (Washington, D.C. : 1974)Pooled it
- Impart: findings from a prison-based model of HIV assisted partner notification in Indonesia.Journal of the International AIDS Society · 2023Trial
- The fourth generation AlereJournal of clinical virology : the official publication of the Pan American Society for Clinical Virology · 2017Trial
- From Law to Practice, Emergency Department Leaders' Experiences With Universal HIV Testing in New York City: A Qualitative Research Brief.The Journal of the Association of Nurses in AIDS Care : JANAC · 2026Article
- Feasibility, Acceptability, and Test Performance of Point-of-Care Nucleic Acid Tests for HIV Testing and Viral Load Monitoring in the United States: Prospective Longitudinal Mixed-Methods Study.JMIR research protocols · 2026Article
- Clinical diagnostic accuracy of the HIV rapid test ACCU-TELL anti-HIV 1 + 2 in sub-Saharan African region.BMC infectious diseases · 2025Article
- DETECTION OF NEW HIV CASES UNDER EPIDEMIC CONTROL - WHEN IS IT THE RIGHT TIME TO REVIEW HIV TESTING ALGORITHMS FOR COUNTRIES NEARING THE 95-95-95 MILESTONES? CASE STUDY -BOTSWANA.African journal of infectious diseases · 2025Article
- A handheld HIV detection platform using paper-based sample preparation and real-time isothermal amplification.Microsystems & nanoengineering · 2024Article
- Laboratory-based evaluation of the 4th-generation AlereTM HIV Combo rapid point-of-care test.PloS one · 2024Article
- Utilization of opportunistic cervical cancer screening in Nigeria.Cancer causes & control : CCC · 2024Article
- Increasing safe clinical spaces and the efforts of clinical research for uninsured and underinsured LGBTQIA2+ patients: A case study of the Rainbow Clinic - a student-run free LGBTQIA2+ clinic.Journal of clinical and translational science · 2023Article
- Article
- Novel miniaturized fluorescence loop-mediated isothermal amplification detection system for rapid on-site virus detection.Frontiers in bioengineering and biotechnology · 2022Article
- Flow-Cytometry Intracellular Detection and Quantification of HIV1 p24 Antigen and Immunocheckpoint Molecules in T Cells among HIV/AIDS Patients.HIV/AIDS (Auckland, N.Z.) · 2022Article
- Predicting, Diagnosing, and Treating Acute and Early HIV Infection in a Public Sector Facility in Eswatini.Journal of acquired immune deficiency syndromes (1999) · 2021Article
- Performance evaluation of the MedMira reveal G4 LAB S/P and POC HIV antibody rapid screening tests using plasma and whole blood specimens.Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology · 2020Article
- Could HIV-1 RNA Testing be an Option as the Second Step in the HIV Diagnostic Algorithm?Sexually transmitted diseases · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
backgroundFDA-approved HIV Antigen/Antibody combo (4th generation) immunoassays (IAs) can identify HIV-1 infections before the Western blot (WB) becomes positive. In the US, increased detection of acute HIV infections has been facilitated by using 4th generation IAs, but there is no FDA-approved 4th generation rapid test (RT). The Alere Determine™ HIV-1/2 Ag/Ab Combo (Determine Combo) RT detects and distinguishes HIV p24 Antigen (Ag) from Antibody (Ab) to HIV-1+HIV-2 and thus has the potential to improve diagnosis of acute HIV infection.
objectiveTo evaluate the ability of Determine Combo RT to detect acute/early HIV-1 infections and HIV-2 antibody in well-characterized plasma specimens. STUDY
designIn HIV-1 seroconverters from the US, Determine Combo reactivity was evaluated by performing the 50% cumulative frequency analysis and by comparing with 3rd and 4th generation IAs' reactivity. HIV-2 plasma specimens from Ivory Coast were tested with Determine Combo.
resultsThe 50% cumulative frequency analysis in 17 seroconverters placed Determine Combo (Ag+/Ab-, Ag+Ab+, Ag-/Ab+) and Ab-component reactivity at 15.5 and 7 days before WB positivity, respectively. In 26 seroconverters, Determine Combo was reactive in 99.0% and 92.5% of 3rd and 4th generation IAs-reactive specimens, respectively. All HIV-2 plasma specimens were Ab-reactive/Ag-non-reactive by Determine Combo.
conclusionsBased on previous results with the same seroconversion panels, combined Ag/Ab reactivity of the Determine Combo appears between FDA-approved 4th and 3rd generation laboratory IAs. These data indicate that this RT could detect HIV-1 infection earlier than other RTs and it performs well in HIV-2 specimens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.